GO:0002025 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002025 describes the biological process in which norepinephrine and epinephrine signaling increases arterial diameter during blood pressure regulation.
• This process is a component of autonomic and vasomotor regulation, integrating central sympathetic outflow with peripheral vascular tone.
• Key molecular players include adrenergic receptors, endothelial nitric oxide synthase (NOS3), and downstream smooth muscle relaxation pathways.
• Dysregulation of this process contributes to hypertension, insulin resistance-related vascular dysfunction, and cerebral hemodynamic changes.
• CGRP and other neuropeptides modulate vascular tone and interact with adrenergic vasodilation mechanisms.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal testing of genes involved in this vasodilatory process.
Description
GO:0002025, norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure, is a biological process that results in an increase in arterial diameter during the norepinephrine-epinephrine response to blood pressure changes. This term captures a specific facet of autonomic vasomotor regulation, where catecholamines released from sympathetic nerves and the adrenal medulla modulate vascular smooth muscle tone to maintain systemic arterial blood pressure. Understanding this process is critical because it sits at the intersection of neural control, endothelial function, and vascular smooth muscle biology. The process is not merely a passive response; it involves active signaling through adrenergic receptors, second messenger systems, and endothelial mediators that ultimately relax arterial smooth muscle. Researchers study GO:0002025 to dissect mechanisms of blood pressure homeostasis, to identify therapeutic targets for hypertension and related cardiovascular diseases, and to understand how systemic factors such as insulin resistance and oxidative stress impair vasodilation. The term is also relevant to cerebral hemodynamics, as acute changes in central blood volume can affect cerebral blood flow through adrenergic mechanisms. Neuropeptides such as CGRP have been shown to modulate vascular tone and may interact with adrenergic pathways, adding another layer of complexity. This article provides a research-grade overview of GO:0002025, covering its definition, molecular participants, disease relevance, and modern methods including CRISPR-based models for functional validation.
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure At A Glance
| GO ID | GO:0002025 |
|---|---|
| GO term | norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure |
| Ontology | biological_process |
| Synonym | noradrenaline-adrenaline vasodilation involved in regulation of blood pressure; norepinephrine-epinephrine vasodilation during blood pressure regulation; vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure |
| Major function | Increase in arterial diameter in response to norepinephrine-epinephrine during blood pressure regulation |
| Related processes | Autonomic vasomotor regulation, adrenergic signaling, endothelial-dependent vasodilation |
| Key mediators | Adrenergic receptors, nitric oxide synthase, smooth muscle relaxation pathways |
| Disease relevance | Hypertension, insulin resistance, cerebral hemodynamic disorders |
What Is GO:0002025?
GO:0002025 is defined as a process that results in an increase in the diameter of an artery during the norepinephrine-epinephrine response to blood pressure change. In other words, when blood pressure fluctuates, norepinephrine and epinephrine act on arterial smooth muscle and endothelial cells to cause vasodilation, helping to regulate systemic arterial blood pressure. This process is distinct from other forms of vasodilation because it is specifically triggered by catecholamines as part of blood pressure regulation.
Why Is norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure Important in Cell Biology?
GO:0002025 is important because it represents a fundamental mechanism by which the autonomic nervous system maintains systemic arterial blood pressure. Dysregulation of this process is implicated in hypertension, where impaired vasodilation contributes to increased vascular resistance. Insulin resistance, a hallmark of metabolic syndrome and diabetes, affects both the kidney and vasculature, altering long-term blood pressure control and potentially disrupting norepinephrine-epinephrine-mediated vasodilation. Additionally, cerebral hemodynamics are sensitive to changes in central blood volume and autonomic tone, and this process may influence cerebral blood flow regulation. Understanding GO:0002025 at the molecular level can reveal therapeutic targets for cardiovascular diseases and guide the development of precision medicine approaches.
• Maintains systemic arterial blood pressure through rapid adjustments in arterial diameter.
• Integrates central autonomic outflow with peripheral vascular responses.
• Involved in the pathogenesis of hypertension via oxidative stress and impaired vasodilation.
• Modulated by insulin resistance, linking metabolic disease to vascular dysfunction.
• Affects cerebral hemodynamics during changes in central blood volume.
• Interacts with neuropeptides such as CGRP, which modulate vascular tone.
• Provides a target for antihypertensive drug development.
• Serves as a model process for studying adrenergic signaling in smooth muscle.
• Relevant to phylogenic determinants of cardiovascular frailty and arterial smooth muscle cell biology.
• Enables CRISPR-based functional genomics of blood pressure regulation.
What Happens During norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure?
Catecholamine Release and Receptor Activation
In simple terms: Norepinephrine and epinephrine are released and bind to receptors on blood vessels.
The process begins with the release of norepinephrine from sympathetic nerve terminals and epinephrine from the adrenal medulla in response to changes in blood pressure. These catecholamines bind to adrenergic receptors on vascular smooth muscle and endothelial cells. Depending on the receptor subtype and vascular bed, this binding can trigger signaling cascades that lead to vasodilation. The autonomic nervous system tightly regulates this release to maintain blood pressure homeostasis.
Endothelial Signaling and Nitric Oxide Production
In simple terms: The inner lining of the artery releases nitric oxide, which helps relax the vessel.
Activation of certain adrenergic receptors on endothelial cells can stimulate the production of nitric oxide (NO) via endothelial nitric oxide synthase (NOS3). NO diffuses to vascular smooth muscle cells and activates soluble guanylate cyclase, leading to increased cyclic GMP and smooth muscle relaxation. This endothelial-dependent mechanism is a key component of norepinephrine-epinephrine-mediated vasodilation. Oxidative stress can impair NO bioavailability, contributing to vascular dysfunction.
Smooth Muscle Relaxation and Arterial Diameter Increase
In simple terms: The muscle in the artery wall relaxes, making the artery wider.
Downstream of NO and other signaling molecules, vascular smooth muscle cells undergo relaxation through decreased intracellular calcium and reduced sensitivity to calcium. This leads to an increase in arterial diameter, reducing vascular resistance and contributing to blood pressure regulation. The process is dynamic and can be modulated by local metabolic factors and neuropeptides such as CGRP.
Integration with Systemic Blood Pressure Regulation
In simple terms: The widening of arteries helps keep blood pressure stable.
The vasodilation mediated by norepinephrine and epinephrine is integrated with other autonomic and hormonal mechanisms to regulate systemic arterial blood pressure. Baroreceptor reflexes and central autonomic networks adjust sympathetic outflow to fine-tune vascular tone. Acute changes in central blood volume can also influence cerebral hemodynamics through similar adrenergic pathways. Insulin resistance and renal oxidative stress can modulate long-term control of arterial blood pressure, potentially affecting this process.
Key Genes Involved in GO:0002025 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure
The following genes and proteins are central to norepinephrine-epinephrine-mediated vasodilation and its regulation of systemic arterial blood pressure.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor; mediates vasodilation in response to epinephrine | Target for studying adrenergic vasodilation and blood pressure regulation |
| ADRA1A | Alpha-1A adrenergic receptor; can mediate vasoconstriction but also involved in complex responses | Used to dissect receptor subtype-specific effects |
| ADRA2A | Alpha-2A adrenergic receptor; presynaptic inhibition of norepinephrine release | Important for feedback control of sympathetic outflow |
| NOS3 | Endothelial nitric oxide synthase; produces NO to relax smooth muscle | Key effector of endothelial-dependent vasodilation |
| GUCY1A1 | Soluble guanylate cyclase subunit; mediates NO signaling | Downstream target of NO in smooth muscle relaxation |
| PRKG1 | cGMP-dependent protein kinase; promotes smooth muscle relaxation | Effector of cGMP signaling in vasodilation |
| CALM1 | Calmodulin; regulates calcium signaling and NOS activity | Modulates calcium-dependent steps in vasodilation |
| CACNA1C | Voltage-gated calcium channel; controls calcium influx in smooth muscle | Determines basal vascular tone and response to vasodilators |
| KCNMA1 | Large-conductance calcium-activated potassium channel; hyperpolarizes smooth muscle | Contributes to membrane potential and relaxation |
| ATP2B1 | Plasma membrane calcium ATPase; extrudes calcium from smooth muscle | Regulates intracellular calcium and vascular tone |
| EDN1 | Endothelin-1; potent vasoconstrictor that counterbalances vasodilation | Studied for its role in hypertension and endothelial dysfunction |
| ACE | Angiotensin-converting enzyme; produces angiotensin II, a vasoconstrictor | Links renin-angiotensin system to blood pressure regulation |
| AGTR1 | Angiotensin II receptor type 1; mediates vasoconstriction | Target for antihypertensive drugs and interaction with adrenergic signaling |
| REN | Renin; rate-limiting enzyme in angiotensin II production | Involved in long-term blood pressure control |
| CALCRL | CGRP receptor component; mediates neuropeptide-induced vasodilation | Interacts with adrenergic pathways in vascular tone regulation |
| RAMP1 | Receptor activity-modifying protein 1; forms CGRP receptor with CALCRL | Modulates CGRP-mediated vasodilation |
| NPPA | Atrial natriuretic peptide; promotes vasodilation and natriuresis | Counter-regulatory hormone in blood pressure regulation |
How Is norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure Regulated?
The process of norepinephrine-epinephrine-mediated vasodilation is regulated at multiple levels. Presynaptic alpha-2 adrenergic receptors inhibit norepinephrine release, providing negative feedback. Post-synaptically, beta-2 adrenergic receptors on smooth muscle and endothelium mediate vasodilation, while alpha-1 receptors can cause vasoconstriction depending on the vascular bed. Endothelial nitric oxide synthase (NOS3) activity is regulated by calcium/calmodulin and phosphorylation, and its expression can be modulated by oxidative stress and insulin resistance. The renin-angiotensin system, through angiotensin II and its receptors, counterbalances vasodilation and influences long-term blood pressure control. Central autonomic networks integrate baroreceptor and chemoreceptor inputs to adjust sympathetic outflow, thereby regulating the overall process. Neuropeptides such as CGRP can also modulate vascular tone and interact with adrenergic signaling.
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NOS3 | Hypertension, endothelial dysfunction | Knockout mouse, overexpression in endothelial cells |
| ADRB2 | Hypertension, asthma, cardiovascular disease | Point mutation knock-in mouse, CRISPR knockout |
| ACE | Hypertension, cardiovascular remodeling | Knockout rat, knock-in for human variants |
| CALCRL | Migraine, vascular tone disorders | Conditional knockout mouse, overexpression |
| AGTR1 | Hypertension, heart failure | Knock-in for human polymorphisms, knockout |
Hypertension and Vascular Dysfunction
Hypertension is characterized by increased vascular resistance and impaired vasodilation. Oxidative stress, a hallmark of hypertension, reduces nitric oxide bioavailability and impairs norepinephrine-epinephrine-mediated vasodilation. Renal oxidative stress also contributes to long-term blood pressure elevation by modulating sodium handling and vascular tone. Insulin resistance, common in metabolic syndrome and diabetes, affects both the kidney and vasculature, leading to altered blood pressure control and endothelial dysfunction. These mechanisms highlight the clinical importance of GO:0002025 in hypertension pathogenesis.
Cerebral Hemodynamics and Blood Flow Regulation
Cerebral blood flow is tightly regulated to meet metabolic demands. Acute increases in central blood volume can affect cerebral hemodynamics, and adrenergic mechanisms may contribute to these responses. Dysregulation of norepinephrine-epinephrine-mediated vasodilation could impair cerebral autoregulation and contribute to cerebrovascular disease. Understanding this process may inform strategies to protect cerebral perfusion in conditions such as hypertension and heart failure.
Migraine and Neuropeptide Interactions
CGRP is a potent vasodilator neuropeptide implicated in migraine pathophysiology. Human studies have shown that CGRP infusion causes vasodilation and migraine-like headaches. The interaction between CGRP and adrenergic vasodilation pathways may modulate vascular tone and pain signaling. Targeting CGRP or its receptor has emerged as a successful therapeutic strategy for migraine, underscoring the clinical relevance of vasodilatory mechanisms.
Cardiovascular Frailty and Aging
Phylogenic determinants of cardiovascular frailty include changes in arterial smooth muscle cells and hemodynamics. Aging is associated with arterial stiffening and impaired vasodilation, which can exacerbate hypertension and increase cardiovascular risk. Studying norepinephrine-epinephrine-mediated vasodilation in the context of aging may reveal mechanisms underlying cardiovascular frailty and identify targets for intervention.
From norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADRB2 impair norepinephrine-epinephrine-mediated vasodilation? | ADRB2 knockout mouse or CRISPR knockout in vascular smooth muscle cells |
| Does a human hypertension-associated point mutation in NOS3 alter NO production? | Point mutation knock-in mouse or isogenic cell lines |
| Can overexpression of NOS3 rescue vasodilation in hypertension? | Endothelial-specific NOS3 overexpression mouse |
| What is the role of CALCRL in CGRP-mediated vasodilation? | CALCRL conditional knockout mouse |
| How does a tagged ADRB2 behave in live imaging? | Tagged knock-in of ADRB2 with fluorescent protein |
| Does knockout of AGTR1 affect blood pressure response to adrenergic stimuli? | AGTR1 knockout rat or mouse |
How to Study the norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Telemetry | Arterial blood pressure and heart rate in conscious animals | Assessing systemic effects of gene knockouts on vasodilation |
| Wire myography | Vasodilation/vasoconstriction of isolated arterial rings | Testing receptor agonists and endothelial function |
| Intravital microscopy | Arterial diameter changes in live animals | Visualizing vasodilation in specific vascular beds |
| Western blot | Protein expression and phosphorylation | Quantifying NOS3, ADRB2, and signaling intermediates |
| RNA-seq | Transcriptomic changes | Identifying genes regulated by adrenergic stimulation |
| CRISPR library screening | Gene essentiality for vasodilation | Discovering novel regulators of the process |
| Bioinformatics pathway analysis | Enriched pathways and networks | Integrating omics data to understand mechanisms |
In Vivo Hemodynamic Measurements
Telemetry and tail-cuff plethysmography are used to measure arterial blood pressure and heart rate in conscious animals. These methods allow assessment of norepinephrine-epinephrine-mediated vasodilation in response to pharmacological agents or genetic modifications. Doppler flowmetry and intravital microscopy can measure arterial diameter changes directly in response to adrenergic stimulation.
Ex Vivo Vascular Reactivity Assays
Isolated arterial rings or pressurized arterioles are used to study vasodilation in response to norepinephrine, epinephrine, or receptor agonists. These assays can dissect endothelial-dependent and independent mechanisms and test the effects of gene knockouts or mutations. Myography provides precise measurements of vessel tone and diameter.
Molecular and Cellular Techniques
Western blotting, immunostaining, and quantitative PCR are used to measure expression of adrenergic receptors, NOS3, and downstream effectors. Phosphorylation-specific antibodies can assess activation of signaling pathways such as Akt and eNOS. FRET-based biosensors and calcium imaging can monitor real-time signaling in living cells.
Genomic and CRISPR Screening Approaches
CRISPR knockout libraries can be screened in endothelial or smooth muscle cells to identify genes required for norepinephrine-epinephrine-mediated vasodilation. RNA-seq and proteomics can reveal transcriptomic and proteomic changes following adrenergic stimulation. Bioinformatics analysis integrates these datasets to identify pathways and networks.
How CRISPR Can Be Used to Study GO:0002025 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure
Knockout
CRISPR knockout of genes such as ADRB2, NOS3, or CALCRL in mice or cell lines can determine their necessity for norepinephrine-epinephrine-mediated vasodilation. For example, NOS3 knockout mice show impaired endothelial-dependent vasodilation, confirming its role in the process. Knockout models are valuable for establishing causal relationships between genes and vascular function.
Point Mutation
Introducing disease-associated point mutations (e.g., in NOS3 or ADRB2) using CRISPR base editing or homology-directed repair allows researchers to study how specific variants affect vasodilatory capacity. Such models can mimic human genetic variations linked to hypertension or altered drug responses.
Knock-in
Knock-in of reporter tags (e.g., fluorescent proteins) or human orthologs enables live imaging of receptor trafficking and signaling. For instance, tagging ADRB2 with GFP allows visualization of its localization and internalization in response to agonists. Knock-in of human ACE or AGTR1 variants can model human blood pressure regulation.
Overexpression
Overexpression of NOS3 or ADRB2 in endothelial or smooth muscle cells can enhance vasodilation and rescue impaired function in disease models. Transgenic overexpression in mice can test whether increasing gene dosage protects against hypertension. Overexpression models are also useful for biochemical studies of signaling pathways.
How EDITGENE Supports norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure Research
Researchers studying norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. CRISPR-based genome editing provides the gold standard for establishing causality by allowing precise knockout, point mutation, knock-in, or overexpression of target genes in relevant cell types and animal models.
Contact EDITGENE today to design your custom CRISPR model for norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure research.
Frequently Asked Questions About norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure
What is GO:0002025?
GO:0002025 is a Gene Ontology biological process term describing norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure. It refers to the increase in arterial diameter triggered by these catecholamines during blood pressure regulation.
What genes are involved in norepinephrine-epinephrine-mediated vasodilation?
Key genes include ADRB2, ADRA1A, ADRA2A, NOS3, GUCY1A1, PRKG1, and CALCRL, among others. These genes encode adrenergic receptors, nitric oxide synthase, and downstream signaling molecules.
How does norepinephrine cause vasodilation?
Norepinephrine can cause vasodilation by activating beta-adrenergic receptors on endothelial and smooth muscle cells, leading to nitric oxide production and smooth muscle relaxation. The effect depends on the vascular bed and receptor subtype.
What is the role of nitric oxide in this process?
Nitric oxide produced by endothelial nitric oxide synthase (NOS3) diffuses to smooth muscle cells, activates guanylate cyclase, and promotes relaxation, thereby increasing arterial diameter.
Which diseases are associated with impaired norepinephrine-epinephrine-mediated vasodilation?
Hypertension, insulin resistance, and cardiovascular frailty are associated with impaired vasodilation. Oxidative stress and endothelial dysfunction contribute to these conditions.
How can CRISPR be used to study this process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of specific genes in norepinephrine-epinephrine-mediated vasodilation.
What methods measure vasodilation in vivo?
Telemetry, tail-cuff plethysmography, Doppler flowmetry, and intravital microscopy are commonly used to measure arterial diameter and blood pressure in live animals.
What is the link between CGRP and this process?
CGRP is a potent vasodilator neuropeptide that can interact with adrenergic pathways. Human studies show CGRP infusion causes vasodilation and migraine-like headaches.
How does insulin resistance affect blood pressure regulation?
Insulin resistance affects the kidney and vasculature, leading to altered sodium handling and endothelial dysfunction, which can impair norepinephrine-epinephrine-mediated vasodilation.
Can overexpression of NOS3 improve vasodilation?
Overexpression of NOS3 in endothelial cells or animal models can enhance nitric oxide production and improve vasodilation, suggesting a potential therapeutic strategy.
Conclusion
GO:0002025, norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure, is a fundamental biological process that integrates autonomic signaling with vascular function. Its dysregulation contributes to hypertension, metabolic vascular disease, and cerebral hemodynamic disorders. Advances in CRISPR genome editing and functional genomics now enable precise dissection of the genes and pathways controlling this process, offering new opportunities for therapeutic intervention. EDITGENE provides comprehensive CRISPR services to support research on this critical blood pressure regulatory mechanism.
References
- 1. Regoli D. 1984. [Polypeptides and antagonists].. Sem Hop 60(14):987-1002 PMID: 6202006
- 2. Reis DJ et al.. 1997. Autonomic and vasomotor regulation.. Int Rev Neurobiol 41:121-49 PMID: 9378586
- 3. Al-Karagholi MA et al.. 2023. The vascular role of CGRP: a systematic review of human studies.. Front Neurol 14:1204734 PMID: 37483452
- 4. Hamza SM et al.. 2014. Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol.. Front Physiol 5:292 PMID: 25140155
- 5. Artunc F et al.. 2016. The impact of insulin resistance on the kidney and vasculature.. Nat Rev Nephrol 12(12):721-737 PMID: 27748389
- 6. Michel JB. 2020. Phylogenic Determinants of Cardiovascular Frailty, Focus on Hemodynamics and Arterial Smooth Muscle Cells.. Physiol Rev 100(4):1779-1837 PMID: 31999509
- 7. Krukoff TL. 1998. Central regulation of autonomic function: no brakes?. Clin Exp Pharmacol Physiol 25(6):474-8 PMID: 9673828
- 8. Ogoh S et al.. 2015. Effect of an acute increase in central blood volume on cerebral hemodynamics.. Am J Physiol Regul Integr Comp Physiol 309(8):R902-11 PMID: 26310936
